Leukocyte Depletion of Autologous Whole Blood (LDAWB-2001)
This study has been completed.
Sponsor:
University of Heidelberg
Collaborator:
Philipps University Marburg Medical Center
Information provided by:
University of Heidelberg
ClinicalTrials.gov Identifier:
NCT00176124
First received: September 11, 2005
Last updated: June 9, 2008
Last verified: June 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Leukocyte depletion of autologous whole blood prior to storage does not reduce infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay but may increase retransfusion perioperatively during hip arthroplasty and allogenic transfusion rate
| Condition | Intervention | Phase |
|---|---|---|
|
Infection Bacterial Infection Sepsis |
Procedure: leukocyte depletion of whole blood Other: Leukocyte filtration/Depletion |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients |
Resource links provided by NLM:
Further study details as provided by University of Heidelberg:
Primary Outcome Measures:
- Comparison of infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Blood loss and transfusion rate [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
| Enrollment: | 1089 |
| Study Start Date: | April 2001 |
| Study Completion Date: | September 2005 |
| Primary Completion Date: | April 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: 1
storage and transfusion of autologous whole blood without leukocyte depletion : Control group
|
Procedure: leukocyte depletion of whole blood |
|
Experimental: 2
storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
|
Procedure: leukocyte depletion of whole blood
Other: Leukocyte filtration/Depletion
leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
Other Name: Fresenius leukocyte depletion whole blood filters
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
• ASA I-III,
- Age 18-85 years,
- Body weight 50-125 kg
- If female, with either a history of an accepted method of anticonception for at least 3 month prior and 1 month following the termination of the study or climacteric or with a negative betA- HCG-Test in urine or serum.
- Preoperative blood donation of at least 2 units (450mL whole blood)
- Preoperative hemoglobin level > 10 mg/dL
- Able and willing to sign informed consent
Exclusion Criteria:
Subjects with a contraindication for preoperative blood donation (PAD) (in 12, PP 36-43).
- systemic infection
- acute bacterial or viral diseases
- anemia (Hb > 11g/dL)
- myocardial infarction within the past 6 month,
- instable angina pectoris
- vascular stenosis (i.e. of the coronary or internal carotid arteries)
- hemodynamic relevant valvular stenosis
- heart failure > NYHA II
- history of strokes or TIA
- steroid therapy,
- immune deficiency,
- hematological or endocrinological disease,
- coagulopathy,
- history of organ transplantation,
- simultaneous participation in a second study
- pregnancy
- membership at Jehovah's Witnesses
- intended use of a cell saver
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00176124
Locations
| Germany | |
| Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine MAnnheim, University of Heidelberg, Germany | |
| Mannheim, Baden-Wuerttemberg, Germany, 68167 | |
| Klinikum Garmisch Partenkirchen | |
| Garmisch Partenkirchen, Bavaria, Germany, 82467 | |
| Institute of Transfusion Medicine and Hemostasiology, University of MArburg | |
| Marburg, Germany, 35043 | |
Sponsors and Collaborators
University of Heidelberg
Philipps University Marburg Medical Center
Investigators
| Study Chair: | Thomas Frietsch, MD, PhD | Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg |
More Information
Additional Information:
Publications:
| Responsible Party: | Thomas Frietsch, MD PhD, University of Heidelberg |
| ClinicalTrials.gov Identifier: | NCT00176124 History of Changes |
| Other Study ID Numbers: | UniKlinMa-TF-2001-1, ISRCTN 99578441 |
| Study First Received: | September 11, 2005 |
| Last Updated: | June 9, 2008 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by University of Heidelberg:
|
leukocyte depletion, autologous transfusion, infection bacterial infection sepsis, antibiotics |
Additional relevant MeSH terms:
|
Bacterial Infections Sepsis Infection |
Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on May 22, 2013